Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06791629
Starting soon Not applicable

Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation

NCT06791629 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Anzhen Hospital
Phase
Not applicable
Started
2025-02-15
Last updated
2025-01-24

Condition(s) studied

Persistent Atrial FibrillationRadiofrequency Catheter AblationPulsed Field Ablation

Investigational drug(s) / intervention(s)

Pulsed Field AblationRadiofrequency Ablation

Pulsed Field Ablation: Patients will be treated with pulsed field ablation for atrial fibrillation.

Radiofrequency Ablation: Patients will be treated with radiofrequency ablation for atrial fibrillation.

Study summary

This clinical trial aims to compare the efficacy and safety of pulsed field ablation and radiofrequency ablation to treat persistent atrial fibrillation in adults.

Participants will:

Undergo pulsed field ablation or radiofrequency ablation. Keep follow-up for at least 12 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18-80 years * Patients with non-valvular persistent atrial fibrillation undergoing their first catheter ablation (AF duration: 3 months to 3 years) * Left atrial diameter on parasternal long-axis view of echocardiogram \< 50 mm * Agree to be randomly assigned to the ablation strategy and able to follow up Exclusion Criteria: * Atrial fibrillation due to reversible causes * LVEF \< 30% * Severe congenital heart disease * Severe liver or kidney dysfunction (eGFR \< 15, Child-Pugh grade 3), or history of dialysis * History of cardiac surgery, such as coronary artery bypass grafting, mechanical valve or prosthetic valve replacement * History of pacemaker implantation, left atrial appendage closure, or patent foramen ovale closure * Contraindications to oral anticoagulation * Contraindications to right or left heart catheterization * Pregnancy * Life expectancy \< 1 year (e.g., advanced malignancy, end-stage renal disease) * Currently enrolled in another trial evaluating medical devices or drugs * Other situations where the investigator determines the subject is unsuitable for the study

Primary outcome measure(s)

  • Freedom from any documented atrial arrhythmia lasting for >30s in the absence of antiarrhythmic therapy in 12 months after the index ablation procedure (excluding a blanking period of 3 months) — From the end of the 3-month blanking period post-ablation to the 12-month follow-up

Trial sites (1)

FacilityCityRegionStatus
Beijing Anzhen Hospital, Capital Medical University Beijing China

More Beijing Anzhen Hospital trials in China

Catheter Ablation of Haemodynamically Not-tolerated Electrical Storm in Structural Heart Disease Starting soon
Arrhythmia Cohort Study Starting soon
Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation Active, not recruiting
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation Recruiting
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE) Active, not recruiting

Other trials for the same condition

3-Dimensional Mapping System: The PULSTAR II Study Active, not recruiting
PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) Recruiting
EGM Guided PFA for PerAF Active, not recruiting
Pulsed Field Ablation for the Treatment of Persistent Atrial Fibrillation: Pulmonary Vein Plus Superior Vena Cava Isolation Versus Pulmonary Vein Isolation Alone-A Prospective, Multicenter, Randomized Controlled Study Starting soon
PFA-based Bi-atrial Maze-like Catheter Ablation for PeAF Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06791629 on ClinicalTrials.gov ↗ ← All trials in China